COVAX

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the World Health Organization, alongside key delivery partner UNICEF. In the Americas, the Pan American Health Organization Revolving Fund is the recognized procurement agent for COVAX.¹⁾

As of April 7, 2021, COVAX had reached supply agreements for 7 COVID-19 vaccine candidates, including:²⁾

• Comirnaty
  • Pfizer-BioNTech
• Covishield
  • Serum Institute of India-AstraZeneca
• Covovax
  • Serum Institute of India-Novavax
• Jcovden
  • Janssen/Johnson & Johnson)
• Nuvaxovid
  • Novavax
• Vaxzevria
  • Oxford Biomedica-AstraZeneca
• Candidate by Sanofi and GlaxoSmithKline

The COVID-19 Vaccines Advance Market Commitment (COVAX AMC) is a financing instrument allowing donors to finance the delivery of vaccines to nations out of the COVAX Facility.

COVAX AMC was presented at the Gavi COVAX AMC 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on April 15, 2021.³⁾ The virtual event was hosted by José Manuel Barroso, Chair of the Gavi Board, U.S. Secretary of State Antony Blinken, and acting United States Agency for International Development USAID Administrator Gloria Steele.⁴⁾

Also in attendance were representatives from:

The program was fully launched by Gavi, the Vaccine Alliance at the Global Vaccine Summit on June 4, 2021.⁶⁾

Financial contributions to the AMC came from:⁷⁾

June 9, 2022 - PANDA by Dr David Bell The World Health Organization (WHO), and the growing pandemic preparedness industry sponsoring it, has faced considerable challenges in maintaining support for its COVID-19 response. It has addressed this difficult situation with simple and uniform messaging. The compliance thus achieved by the WHO has been vital to achieving a successful concentration of wealth, benefitting not just its major sponsors, but also the army of global health staff who have remained obedient throughout.

Threatening this progress, a skeptical minority within the public sphere have been using evidence and rational argument to undermine the pandemic industry’s potential. As the pandemic preparedness and response narrative is poorly defensible on rational criteria, such criticism and opposition must be dealt with and dismissed by other means. This is being achieved through the creation of a dogma around mass COVID-19 vaccination sufficiently separated from reality as to render the normal processes of debate irrelevant. If the gap between pandemic messaging and reality can be kept sufficiently wide, few passengers can step off, and this lucrative gravy train becomes unstoppable.

Small lies can be argued against, big lies become matters of faith. ⁸⁾